VAB · KOL · Patient Advisory
Specialist Insight at Global Scale
In rare disease drug development and commercialization, the experts who matter most are often scattered across a dozen countries, see fewer than fifty patients a year, and are perpetually overcommitted. Convening them in a single room is logistically prohibitive and scientifically unnecessary.
MedPanel’s rare disease virtual advisory boards bring the world’s leading specialists—verified KOLs, treating physicians, and where the science demands it, patients and caregivers—into a structured, compliance-ready format that generates the clinical, strategic, and commercial insight your program needs, without the friction of in-person logistics. For pharma and biotech sponsors operating in rare and ultra-rare disease, a well-designed VAB is not a meeting. It is a decision-support instrument.
KOL-only boards
Verified specialists for label, algorithm, and pipeline positioning.
Patient-inclusive
IRB-ready patient and caregiver advisory—not focus groups.
Mixed boards
Clinical and lived experience for burden, adherence, and awareness.
Full compliance
FMV, agreements, COI, and audit-ready documentation.
What a Rare Disease VAB Delivers That a Standard Advisory Board Cannot
A general-purpose advisory board populated from a commercial panel reflects general opinion. A rare disease virtual advisory board, designed and recruited correctly, reflects verified expertise—and that distinction determines whether the output can be used to inform regulatory strategy, label decisions, medical education design, or launch sequencing.
The practical differences compound quickly. Standard advisory board vendors recruit from self-reported databases: physicians who claim a rare disease specialty but whose actual patient exposure is unmeasured and unverified. MedPanel’s panel is credentialed. Every advisor is validated against licensure, institutional affiliation, and documented rare disease practice activity before a single invitation is sent.
Beyond panel quality, rare disease VABs require a different facilitation model. The questions are more nuanced, the diagnostic and treatment landscape more contested, and the clinical heterogeneity more pronounced than in common diseases. MedPanel’s moderators are trained in rare disease subject matter, not rotated from a general qualitative team, which means the conversation reaches the level of specificity that pharma and biotech medical affairs teams actually need.
Related: Rare disease research overview · Physician recruitment and engagement research
KOL-Only, Patient-Inclusive, and Mixed VAB Formats
The right advisory board format depends on the strategic question the program needs to answer. MedPanel designs and executes three primary rare disease VAB structures, each with distinct participant profiles, facilitation approaches, and deliverable outputs.
KOL-only advisory boards
Five to ten verified specialists address pre-NDA/MAA label input, treatment algorithm consensus, pipeline positioning, and medical education gap analysis ahead of launch.
Patient-inclusive advisory boards
Verified patients and caregivers—recruited through IRB-ready infrastructure, not focus groups—for PRO validation, PSP design, label comprehension, and post-approval safety communication testing.
Mixed KOL and patient boards
When clinical and lived experience intersect: treatment burden, adherence barriers, shared decision-making, and disease awareness—with facilitation designed to balance power dynamics.
Across all three formats, output deliverables are scoped at engagement initiation: verbatim transcripts, thematic analysis reports, consensus scoring summaries, and—where required for regulatory or internal review purposes—full video recordings with timestamped annotation.
Related: Rare disease patient recruitment · Physician recruitment and engagement research
Compliance, Fair Market Value, and Sponsor Documentation
For pharmaceutical and biotech sponsors, advisory board compliance is not a process formality—it is a material legal and reputational risk if managed incorrectly. Rare disease programs carry elevated scrutiny because advisor pools are small, KOL relationships are long-term, and the line between legitimate scientific exchange and improper influence requires active management.
Fair market value (FMV) compensation
Benchmarked by specialty, geography, and engagement type—documented for ABPI, PhRMA, EFPIA, and OIG guidance.
Consulting agreements & acknowledgements
Prepared and executed prior to each engagement, available for sponsor audit.
Conflict-of-interest management
Disclosure collection integrated into advisor onboarding workflow.
IRB review pathway
For boards involving patients, caregivers, or human subjects research thresholds.
Data handling protocols
HIPAA, GDPR, and local data protection across all participant geographies.
Sponsors receive a complete documentation package for each advisory board—advisor agreements, FMV records, attendance logs, conflict disclosures, and moderation notes—formatted for internal compliance review and third-party audit. For rare disease programs with heightened regulatory visibility, this documentation standard is not optional. MedPanel builds it in by design.
Related: Rare disease research overview · Rare disease patient recruitment
Platform, Moderation, Facilitation, and Analysis Workflow
A rare disease virtual advisory board is only as effective as the environment in which it runs. Technical failure, poor moderation discipline, or an analysis workflow that loses nuance in aggregation can render a high-cost advisory engagement strategically inert.
MedPanel’s end-to-end VAB workflow covers every stage from advisor identification to final report delivery. Thematic analysis is conducted by MedPanel’s research team—not outsourced to a general qualitative vendor—and delivered as a structured advisory report with direct strategic implications mapped to the sponsor’s original brief.
Timelines from scope confirmation to final report delivery typically range from six to ten weeks, depending on advisory board format, participant geography, and report specification.
Recruitment and verification
Advisors identified from MedPanel’s credentialed panel or sourced de novo; eligibility, availability, and COI confirmed before scheduling.
Pre-board preparation
Condition-specific briefing materials, discussion guides, and pre-reads; plain-language prep for patient and caregiver advisors.
Platform and facilitation
Secure, HIPAA-compliant video; rare disease–trained facilitator; 90–120 minute cadence with breakout formats for mixed boards.
Recording and documentation
Full video, verbatim transcripts, and real-time moderation notes under sponsor-specified data handling protocols.
Analysis and reporting
Thematic analysis and structured advisory report with strategic implications mapped to your brief.
Why Rare Disease Requires a Specialist Advisory Board Partner
The market research and advisory board industry is large. The subset of that industry with genuine rare disease capability—verified specialist panels, IRB-ready patient recruitment, compliance infrastructure calibrated to pharma sponsor requirements, and moderation depth in rare and ultra-rare conditions—is small.
MedPanel has operated in rare disease research for more than 20 years. Our advisor panel is verified, not self-reported. Our patient recruitment meets IRB standards. Our compliance documentation is built for audit, not assembled after the fact. And our research record—seven peer-reviewed publications in indexed journals—reflects a scientific rigor that separates MedPanel from commercial advisory board vendors whose primary competency is scheduling, not insight.
For rare disease programs where the difference between informed and uninformed decisions can be measured in years of development time and hundreds of millions in capital allocation, the quality of your advisory board infrastructure is not a vendor selection detail. It is a strategic input.
Related: Physician recruitment and engagement research · Rare disease research overview
Get started
Scope Your Rare Disease Advisory Board
Whether you need a KOL consensus panel ahead of a regulatory submission, a patient advisory board to inform your PRO strategy, or a mixed board to map the treatment burden landscape in a specific rare condition, MedPanel’s team will design the engagement format, recruit the right advisors, and deliver analysis that moves your program forward.
KOL-only, patient-inclusive, or mixed format scoping
Verified advisor recruitment and compliance documentation
Rare disease–trained facilitation and thematic analysis
Typical delivery in six to ten weeks
Tell us your condition, your strategic question, and your timeline. We will scope a rare disease virtual advisory board built to answer it. Email info@medpanel.com or use the button above to request a consultation.